| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2012 | 2011 | 2010 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,5 M € | +1.8% | 3,4 M € | -22.6% | 4,5 M € | +63.3% | 2,7 M € | +100.5% | 1,4 M € | -18.3% | 1,7 M € | -15.0% | 2,0 M € | -3.9% | 2,0 M € | +13.7% | 1,8 M € | +15.7% | 1,6 M € | +23.2% | 1,3 M € | +74.5% | 721,2 k € | +21.5% | 593,9 k € | |
| EBITDA | 221,2 k € | +52.3% | 145,2 k € | +24.7% | 116,4 k € | +9.5% | 106,4 k € | +12.6% | 94,4 k € | -13.4% | 109,0 k € | -14.9% | 128,1 k € | +0.4% | 127,7 k € | +13.3% | 112,7 k € | +15.1% | 97,9 k € | +24.7% | 78,5 k € | +70.3% | 46,1 k € | +29.0% | 35,8 k € | |
| Operating profit | 213,4 k € | +50.7% | 141,7 k € | +29.5% | 109,4 k € | +9.8% | 99,6 k € | +14.1% | 87,2 k € | -17.1% | 105,2 k € | -15.4% | 124,4 k € | -0.8% | 125,4 k € | +13.1% | 110,9 k € | +15.3% | 96,2 k € | +22.5% | 78,5 k € | +70.3% | 46,1 k € | +29.0% | 35,8 k € | |
| Profit/loss | 133,3 k € | +58.5% | 84,1 k € | +39.3% | 60,3 k € | +7.6% | 56,1 k € | +15.1% | 48,7 k € | +4.2% | 46,8 k € | -34.1% | 71,0 k € | +21.4% | 58,5 k € | +19.3% | 49,0 k € | +11.7% | 43,9 k € | +43.8% | 30,5 k € | +43.8% | 21,2 k € | +7.7% | 19,7 k € | |
| Equity | 684,2 k € | +24.2% | 550,9 k € | +18.0% | 466,9 k € | +14.8% | 406,6 k € | +16.0% | 350,5 k € | +16.1% | 301,8 k € | +18.3% | 255,0 k € | +38.6% | 184,0 k € | -16.4% | 220,2 k € | +28.6% | 171,2 k € | +90.2% | 90,0 k € | +51.3% | 59,5 k € | +55.5% | 38,3 k € | |
| Total assets | 1,2 M € | +11.6% | 1,1 M € | +42.2% | 762,4 k € | -42.2% | 1,3 M € | +104.4% | 645,3 k € | +30.0% | 496,4 k € | -46.5% | 928,1 k € | +32.7% | 699,4 k € | +33.2% | 525,1 k € | +34.2% | 391,3 k € | +7.9% | 362,7 k € | +25.8% | 288,2 k € | +71.6% | 168,0 k € | |
| Cash | 195,1 k € | +507.2% | 32,1 k € | -93.2% | 471,1 k € | -57.0% | 1,1 M € | +226.6% | 335,8 k € | +74.5% | 192,4 k € | -67.5% | 592,5 k € | +67.6% | 353,5 k € | +267.5% | 96,2 k € | -33.3% | 144,3 k € | +39.6% | 103,4 k € | -22.2% | 132,9 k € | +64.8% | 80,6 k € | |
| Debts | 525,9 k € | -1.4% | 533,3 k € | +80.5% | 295,5 k € | -67.6% | 912,7 k € | +209.6% | 294,8 k € | +51.5% | 194,6 k € | -71.1% | 673,1 k € | +30.6% | 515,5 k € | +69.1% | 304,9 k € | +38.5% | 220,1 k € | -19.3% | 272,7 k € | +19.2% | 228,8 k € | +76.3% | 129,7 k € | |
| Staff | 7,7 | 6,4 | 6,6 | 5,1 | 3,7 | 4,1 | 5,8 | 6,3 | 6,5 | 7,4 | 3,8 | 2,8 | 1,1 | |||||||||||||
Private limited company · Mechelen · incorporated on 17/12/2009 · 7,7 ETP
Private limited company profitable and well capitalised. Cash position rising (+507.2%).
Solid counterparty for a standard engagement.
ORION PHARMA is a Private limited company incorporated in 2009. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Mechelen. It employs on average 7,7 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette